- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:54 | Eupraxia Pharmaceuticals stock maintains Overweight rating at Cantor Fitzgerald | 3 | Investing.com | ||
| Mo | Eupraxia reports positive data from highest dose cohort in EoE trial | 1 | Investing.com | ||
| Mo | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs | 63 | GlobeNewswire (Europe) | Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients... ► Artikel lesen | |
| EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Mo | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| Do | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals closes $80.5-million offering | 1 | Stockwatch | ||
| Mi | Eupraxia Pharmaceuticals schließt Kapitalerhöhung über 80,5 Millionen US-Dollar ab | 1 | Investing.com Deutsch | ||
| Mi | Eupraxia pharmaceuticals raises $80.5 million in public offering | 2 | Investing.com | ||
| Mi | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option | 273 | GlobeNewswire (Europe) | VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 23.09. | Eupraxia Pharmaceuticals: Aktie fällt nach Platzierung einer 70-Millionen-Dollar-Kapitalerhöhung | 2 | Investing.com Deutsch | ||
| 23.09. | Eupraxia Pharmaceuticals stock falls after pricing $70 million offering | 1 | Investing.com | ||
| 23.09. | Eupraxia Pharmaceuticals Inc: Eupraxia prices shares of offering at $5.50 (U.S.) | 1 | Stockwatch | ||
| 23.09. | Eupraxia Pharmaceuticals prices $70M share offering | 1 | Seeking Alpha | ||
| 23.09. | Eupraxia platziert Kapitalerhöhung über 70 Mio. US-Dollar zu 5,50 US-Dollar je Aktie | 1 | Investing.com Deutsch | ||
| 23.09. | Eupraxia prices $70 million public offering at $5.50 per share | 1 | Investing.com | ||
| 23.09. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares | 187 | GlobeNewswire (Europe) | VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 23.09. | Eupraxia Pharmaceuticals Inc: Eupraxia files preliminary prospectus for offering | 1 | Stockwatch | ||
| 22.09. | Eupraxia Pharmaceuticals plant öffentliche Platzierung von Stammaktien | 1 | Investing.com Deutsch | ||
| 22.09. | Eupraxia Pharmaceuticals announces public offering of common shares | 1 | Seeking Alpha | ||
| 22.09. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares | 1 | GlobeNewswire (USA) | ||
| 19.09. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 2 | SEC Filings |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS | 18,620 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 6,245 | 0,00 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
| IMMUNOVANT | 16,060 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| NUVALENT | 84,84 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 42,655 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| EVOTEC | 6,158 | +1,45 % | adidas, Evotec, Gerresheimer, Hensoldt, TeamViewer, TUI - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,915 | 0,00 % | Looking for the Next Big Pop? Here's Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce | ||
| QIAGEN | 37,335 | -0,76 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
| DYNE THERAPEUTICS | 12,370 | 0,00 % | Dyne: Ministry Of Health In Japan Grants Orphan Drug Designation For DYNE-251 | ||
| HARMONY BIOSCIENCES | 27,640 | 0,00 % | Deep Dive Into Harmony Biosciences Holdings Stock: Analyst Perspectives (6 Ratings) | ||
| VALNEVA | 5,040 | +10,24 % | Valneva: Chikungunya-Impfstoff zeigt über vier Jahre stabile Wirksamkeit | Valneva hat neue Daten zur Antikörperpersistenz seines Chikungunya-Impfstoffs IXCHIQ veröffentlicht. Vier Jahre nach einer einmaligen Impfung zeigten nach Angaben des Biotech-Unternehmens vom Dienstag... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,155 | 0,00 % | Summit Therapeutics: HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 | Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS... ► Artikel lesen | |
| RELAY THERAPEUTICS | 5,190 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates | Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,370 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| TREVI THERAPEUTICS | 8,950 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen |
EUPRAXIA PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,040 (+0,84 %) liegt der Kurs bei 4,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EUPRAXIA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.